Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
about
Certolizumab pegol (CDP870) for rheumatoid arthritis in adultsAn evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapyBiologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials.Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID studyPost-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritisCertolizumab pegol for the treatment of psoriatic arthritis.Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor iShort-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis.Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritis.Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritisEarly response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies
P2860
Q24193535-759A3B1E-6982-47E9-B3D2-064B354C143CQ28074393-A0B3D929-6BD9-44C7-8042-58F235BF995FQ30235341-732EEB34-2C29-45FC-9A52-B723E1C5E41EQ34769757-EAF34618-4091-40E0-BCF2-62D8F17C4A0AQ35758262-94C8FD28-4E26-4D32-89BB-1403D7F06466Q36014642-2EB9377E-18D7-43D8-830D-FDA7CE9F81DAQ36195284-F50933B4-B5ED-4599-BE3E-2C5019336611Q36475622-92EB644F-CBFB-481C-8631-F95B2D2D068EQ36761836-3EE7468F-4E8D-4EF5-A97E-36088666F2EFQ36981521-58857B3C-E24B-4787-BD12-91C40007FC60Q38344194-1BEE5EEA-DEFD-4F1F-AFCB-464D14ED2BF6Q38632657-408929A9-825D-4739-BB86-EA614E96B1D6Q38939820-D702E34D-77E8-4CF7-A483-EB6934973676Q39333743-AF891285-5119-4EC5-91E1-F891DC1DBFE4Q39796994-6F130FC7-7D64-4CFC-A446-23EA8DC219AEQ40374825-FA49111B-E971-4D14-A3C0-17A47040FF62Q47836056-F997F083-AD43-48AD-997D-316DCE35387BQ48744497-490B7371-1520-4839-9C4B-AD7E79B31DA0Q51641849-34F979C4-62D8-410D-BECA-587657778E6FQ57330038-6C867310-308C-4957-BFBC-A2A5348725A5Q58204670-ECE47359-8863-443A-B46F-D62041EBDEF4
P2860
Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Efficacy and safety of certoli ...... zed, placebo-controlled trial.
@en
Efficacy and safety of certoli ...... zed, placebo-controlled trial.
@nl
type
label
Efficacy and safety of certoli ...... zed, placebo-controlled trial.
@en
Efficacy and safety of certoli ...... zed, placebo-controlled trial.
@nl
prefLabel
Efficacy and safety of certoli ...... zed, placebo-controlled trial.
@en
Efficacy and safety of certoli ...... zed, placebo-controlled trial.
@nl
P2093
P2860
P50
P1433
P1476
Efficacy and safety of certoli ...... zed, placebo-controlled trial.
@en
P2093
Akira Watanabe
Hideki Origasa
Hisashi Yamanaka
Katsumi Eguchi
Kazuhiko Yamamoto
Naoki Ishiguro
Nobuyuki Miyasaka
Toshiharu Shoji
Yoshiharu Sakamaki
Yoshiya Tanaka
P2860
P304
P356
10.3109/14397595.2013.864224
P577
2013-12-09T00:00:00Z